Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Articles|June 24, 2025

MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes

Author(s)Davy James

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.

Key Takeaways

  • Up to 20% Weight Loss Achieved with Monthly Dosing. MariTide demonstrated mean weight reductions of up to 20% in participants with obesity without type 2 diabetes and up to 17% in those with both obesity and type 2 diabetes, supporting its potential as a high-efficacy obesity treatment.
  • Improved Glycemic Control in Obesity–Diabetes Cohort. Participants with type 2 diabetes saw HbA1c reductions of up to 1.6 percentage points, with a high percentage achieving normoglycemia after 52 weeks of MariTide treatment.
  • Favorable Safety Profile with Dose Escalation Strategy. No new safety signals were reported; gastrointestinal adverse effects were reduced with lower starting doses and gradual dose escalation, informing the Phase III MARITIME trial design.

Results from a Phase II clinical trial (NCT05669599) evaluating the novel therapy MariTide (maridebart cafraglutide; Amgen) showed significant and sustained weight loss in adults with obesity both with or without type 2 diabetes.1,2

Once-Monthly MariTide Shows Promising Weight Loss Results in Obesity and Type 2 Diabetes Patients

The findings, also published by The New England Journal of Medicine (NEJM), show the drug’s potential to become a durable, lower-burden treatment for obesity and metabolic disease, pending confirmation in ongoing Phase III trials, according to trial investigators.3

"MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week Phase II study and meaningful improvements in cardiometabolic risk factors, representing a defining advance for the obesity field," Jay Bradner, MD, executive vice president of Research and Development at Amgen, said in a press release. "These results, alongside the Phase I Pharmacokinetics Low Dose Initiation data, have shaped our Phase III MARITIME program. MariTide's monthly or less frequent dosing has the potential to improve adherence and long-term weight control, providing the opportunity to optimize health outcomes for people living with obesity, type 2 diabetes and related conditions."1

How Does MariTide Compare to Other GLP-1 Medications?

MariTide is a bispecific molecule produced by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers. Results from a Phase I trial (NCT04478708) indicated the drug produced longer lasting and durable reductions in body weight compared to the popular GLP-1 agonists currently on the market: Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide).4

“Although both GIP receptor agonism and antagonism lead to weight reduction, especially when combined with GLP-1 receptor agonism, genetic evidence indicates that GIP receptor variants that are linked to reduced receptor signaling are associated with a lower body-mass index,” the study authors wrote in NEJM. “Maridebart cafraglutide, composed of two identical GLP-1 peptide analogues conjugated to a single monoclonal antibody antagonist to the GIP receptor, has a half-life of approximately 21 days (approximately 3 times as long as the longest-acting Food and Drug Administration–approved once-weekly medications for obesity), which supports monthly or less frequent administration.”3

MariTide Phase II Trial Design and Dosing

  • The current, double-blind, randomized, placebo-controlled, dose-ranging trial enrolled 592 participants, who were divided into 11 groups as two cohorts comprised of those with obesity or those with obesity and type 2 diabetes.
  • Patients with obesity (n = 465) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive subcutaneous (SC) MariTide at a dose of 140, 280, or 420 mg every four weeks without dose escalation; 420 mg every eight weeks without dose escalation; 420 mg every four weeks with four-week dose escalation; 420 mg every four weeks with 12-week dose escalation; or placebo.
  • Patients with both obesity and type 2 diabetes (n = 127) were randomly assigned in a 1:1:1:1 ratio to receive SC MariTide at a dose of 140, 280, or 420 mg every four weeks without dose escalation or placebo.
  • The trial’s primary endpoint was percent change in body weight from baseline to week 52.

MariTide Phase II Trial Shows Up to 20% Weight Loss in Obesity and Type 2 Diabetes Patients

  • Results from the obesity cohort show a mean percent change in body weight from baseline to week 52 ranged from −12.3% (95% confidence interval [CI], −15.0 to −9.7) to −16.2% (95% CI, −18.9 to −13.5) among those administered MariTide versus −2.5% (95% CI, −4.2 to −0.7) among those administered placebo.
  • Results from the obesity–diabetes cohort show a mean percent change in body weight from baseline to week 52 that ranged from −8.4% (95% CI, −11.0 to −5.7) to −12.3% (95% CI, −15.3 to −9.2) among those administered MariTide versus −1.7% (95% CI, −2.9 to −0.6) among those administered placebo.
  • Mean change in glycated hemoglobin level in the obesity–diabetes cohort was −1.2 to −1.6 percentage points among those administered MariTide compared to 0.1 percentage points among those administered placebo.
  • In total, investigators reported average weight loss of approximately 20% among patients with obesity without type 2 diabetes in the MariTide cohort compared to 2.6% in the placebo cohort.
  • Among patients with obesity with type 2 diabetes, investigators reported average weight loss of up to approximately 17% compared to 1.4% in the placebo cohort, per the efficacy estimand.1

MariTide Safety Profile and Implications for Phase III MARITIME Program

  • In terms of safety, gastrointestinal adverse events were common among those administered MariTide but occurred less frequently with dose escalation and a lower starting dose, according to the trial investigators.
  • There were no new or unexpected safety signals reported.

“A consistent observation from clinical trials with nutrient-stimulated hormone receptor modulators is that persons with obesity and type 2 diabetes lose less weight than those without type 2 diabetes; the mechanisms of the response are unknown,” the study authors concluded. “We found that participants with type 2 diabetes lost only slightly less weight than those without type 2 diabetes (differences of approximately 3 to 4 percentage points between the obesity cohort and the obesity–diabetes cohort). Participants in the obesity–diabetes cohort lost on average up to 12% of body weight on the basis of the treatment policy estimand (up to 17% on the basis of the efficacy estimand), with few agents to date resulting in such a magnitude of reduction in persons with type 2 diabetes and none that are administered once monthly.”3

References

1. Results From Amgen's Phase 2 Obesity Study of Monthly Maritide Presented at the American Diabetes Association 85th Scientific Sessions. News release. Amgen. June 23, 2025. Accessed June 23, 2025. https://www.prnewswire.com/news-releases/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions-302487811.html

2. Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. ClinicalTrials.gov. Updated February 20, 2025. Accessed June 23, 2025. https://clinicaltrials.gov/study/NCT05669599

3. Jastreboff A., et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med 2025. doi/full/10.1056/NEJMoa2504214

4. Véniant, M.M., et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab 2024. https://doi.org/10.1038/s42255-023-00966-w


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.